The global DNA Synthesis Market was valued at USD 3.59 billion in 2023 and is projected to surge to USD 15.48 billion by 2032, registering a strong compound annual growth rate (CAGR) of 17.66% during the forecast period from 2024 to 2032. This remarkable expansion reflects the rapid integration of synthetic DNA technologies across genomics, molecular diagnostics, biopharmaceutical research, and next-generation therapeutics worldwide.
Market growth is being propelled by increasing investments in life sciences research, rising prevalence of genetic and chronic diseases, and growing demand for high-precision tools in gene editing, sequencing, and synthetic biology. Advancements in oligonucleotide and gene synthesis technologies are enabling faster, more accurate, and scalable DNA production, supporting applications ranging from basic research to advanced clinical therapeutics.
Get free Sample Report@ https://www.snsinsider.com/sample-request/3832
DNA Synthesis Market Key Segmentation Insights
By Service
The oligonucleotide synthesis segment dominated the market in 2023, driven by its indispensable role in molecular biology workflows such as PCR, DNA sequencing, cloning, and gene expression analysis. Growing emphasis on genomics research, early disease diagnosis, and personalized medicine continues to boost demand for high-quality oligonucleotides. Increased awareness of genetic disorders has further strengthened their use in both diagnostic and therapeutic applications. Notably, initiatives such as UC San Diego’s Gene Therapy Initiative, supported by a USD 5 million philanthropic investment, underscore the rising institutional focus on genetic research and innovation.
The gene synthesis segment is expected to register the highest CAGR of 16.7% over the forecast period. Custom gene synthesis and gene library synthesis are increasingly adopted in gene therapy, enabling targeted treatment approaches through gene replacement, repair, or modification. These capabilities allow researchers to clone synthetic genes into customized vectors, optimize gene expression, and enhance therapeutic specificity, accelerating progress in precision medicine.
By Application
In 2023, research and development accounted for 63.3% of total market revenue, reflecting the extensive use of DNA synthesis in global research programs. Synthetic DNA plays a foundational role in drug discovery, genetic testing, genome editing, and biopharmaceutical development. The rapid adoption of CRISPR-based technologies has further amplified demand, supporting applications such as gene knockout studies, functional genomics, and experimental therapeutics.
The therapeutics segment represents the fastest-growing application area, projected to expand at a CAGR of 16.41% through 2032. DNA synthesis enables rapid and accurate development of customized therapeutic targets, including synthetic gene circuits and engineered enzymes. Rising demand for personalized treatments for cancer and rare genetic disorders is positioning therapeutics as a major growth engine within the DNA synthesis ecosystem.
Regional Analysis
North America led the DNA synthesis market in 2023, accounting for 39.7% of global revenue, supported by advanced healthcare infrastructure, strong R&D funding, and high public awareness. The United States remains a key contributor, with increasing use of synthetic DNA and RNA in diagnostics, research, and gene-based therapies, alongside a competitive landscape of established players and innovative startups.
Europe continues to demonstrate strong growth potential, driven by government support, robust biotechnology infrastructure, and expanding gene therapy adoption. The UK’s progressive regulatory environment, including approvals for CRISPR-based therapies such as Casgevy, highlights regional momentum. France’s focus on cancer and cardiovascular research further fuels demand for oligonucleotide-based diagnostics and personalized treatments.
The Asia Pacific region is projected to experience the fastest growth, with a CAGR of 17.5% from 2024 to 2032. China leads the region with an estimated 21.4% CAGR, supported by CRO expansion and manufacturing scale-ups. Japan’s aging population and emphasis on personalized medicine, along with India’s high prevalence of genetic disorders and supportive government initiatives, create a favorable outlook for DNA synthesis adoption.
Competitive Landscape and Recent Developments
The DNA synthesis market is highly competitive, with leading players focusing on technological innovation, strategic collaborations, and capacity expansion. Key companies include Thermo Fisher Scientific, Twist Bioscience, GenScript Biotech Corporation, Integrated DNA Technologies, Eurofins Scientific, and QIAGEN, among others.
Recent developments highlight continued innovation, including the launch of enzymatic DNA synthesis licensing programs, strategic partnerships in next-generation sequencing workflows, and expanded stability and genomics services across major facilities. These advancements are expected to enhance production efficiency, reduce synthesis costs, and broaden application scope across research and clinical settings.
Market Outlook
With sustained investments in genomics, accelerating adoption of gene therapies, and expanding applications in diagnostics and therapeutics, the DNA synthesis market is poised for transformative growth through 2032. Continuous innovation and regional expansion will remain critical in shaping the future trajectory of this rapidly evolving industry.
Other Trending Reports
Smart Therapeutic Devices Market
Foot Orthotic Insoles Market Growth
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
Contact Us:
Rohan Jadhav – Principal Consultant
Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Email: [email protected]
